SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as former President Trump's renewed threats of tariffs on NATO allies, particularly over the acquisition of Greenland, spark fears of a trade war with Europe. This escalating geopolitical tension is causing widespread market jitters and calls for caution, though many investors are also discussing it as a potential "buy the dip" opportunity for growth stocks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is trending strongly as renewed geopolitical tensions, including recent tariff threats concerning European countries over Greenland, fuel a broad flight to safety. The community views gold as a crucial hedge against eroding fiat currency confidence and economic instability, driving prices to consistent new highs. Many are discussing significant further appreciation as these global uncertainties persist.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amidst a broader software sector selloff, with community discussion centered on whether AI advancements pose a threat or opportunity. Recent news of a key OpenAI partnership and the strategic acquisition of cybersecurity firm Armis, alongside positive analyst reiterations, fuels debate over the stock's oversold status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 19.2% in December

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling...

Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 107.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?

Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Time to Buy?

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Here's What Happened...

Morning Market Brief: Infrastructure, AI, and Biotech Signal a Scale-Up Cycle Is Underway

Today's top stock market headlines cover Infrastructure, AI, and Biotech

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are covering the firm, Marketbeat.com reports...

Notable Friday Option Activity: DAWN, XPO, UUUU

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Day One Biopharmaceuticals Inc (Symbol: DAWN), where a total volume of 13,188...

Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.5% - Still a Buy?

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 5.5% - Time to Buy...

Day One Biopharmaceuticals Target of Unusually Large Options Trading (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders purchased 5,027 call options on the stock. This represents...

Braidwell LP Has $14.18 Million Position in Day One Biopharmaceuticals, Inc. $DAWN

Braidwell LP reduced its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 38.3% during the second quarter, according to the company in its most recent 13F filing...

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

DAWN
Day One Biopharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DAWN News

DAWNDay One Biopharmaceuticals Inc